Praful Kumar Ravi, M.B.,BChir
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Transitional Cell | 5 | 2024 | 799 | 2.040 |
Why?
|
| Prostate-Specific Antigen | 13 | 2024 | 2487 | 1.950 |
Why?
|
| Prostatic Neoplasms | 23 | 2024 | 11230 | 1.830 |
Why?
|
| Urinary Bladder Neoplasms | 11 | 2024 | 2251 | 1.790 |
Why?
|
| Androgen Antagonists | 10 | 2024 | 1421 | 1.780 |
Why?
|
| Prostatectomy | 12 | 2024 | 1841 | 1.040 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2022 | 3200 | 0.860 |
Why?
|
| Kidney Neoplasms | 10 | 2022 | 4300 | 0.810 |
Why?
|
| Seminoma | 3 | 2023 | 136 | 0.790 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2024 | 9442 | 0.750 |
Why?
|
| Cystectomy | 7 | 2024 | 645 | 0.740 |
Why?
|
| Neoadjuvant Therapy | 5 | 2024 | 2909 | 0.730 |
Why?
|
| Testicular Neoplasms | 4 | 2023 | 808 | 0.680 |
Why?
|
| Lutetium | 3 | 2024 | 38 | 0.660 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2018 | 46 | 0.620 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2024 | 1535 | 0.580 |
Why?
|
| Immunoconjugates | 2 | 2023 | 976 | 0.530 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2023 | 1943 | 0.510 |
Why?
|
| Autoantibodies | 1 | 2024 | 2120 | 0.480 |
Why?
|
| Penile Neoplasms | 1 | 2016 | 158 | 0.480 |
Why?
|
| Multiple Myeloma | 3 | 2018 | 5196 | 0.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 11886 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 10400 | 0.450 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 2 | 2024 | 68 | 0.440 |
Why?
|
| Dipeptides | 3 | 2024 | 386 | 0.430 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2024 | 125 | 0.420 |
Why?
|
| Phenylthiohydantoin | 2 | 2024 | 215 | 0.410 |
Why?
|
| Periodicity | 1 | 2014 | 348 | 0.410 |
Why?
|
| Male | 63 | 2024 | 365203 | 0.390 |
Why?
|
| Nephrectomy | 5 | 2022 | 949 | 0.380 |
Why?
|
| Aged | 43 | 2024 | 171786 | 0.340 |
Why?
|
| Hospitals, Teaching | 2 | 2014 | 1159 | 0.340 |
Why?
|
| Vinblastine | 2 | 2021 | 487 | 0.340 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 1181 | 0.330 |
Why?
|
| Aged, 80 and over | 24 | 2024 | 59739 | 0.320 |
Why?
|
| Neoplasm Metastasis | 7 | 2023 | 4926 | 0.320 |
Why?
|
| Nitriles | 2 | 2024 | 990 | 0.320 |
Why?
|
| Neoplasm Staging | 6 | 2023 | 11262 | 0.320 |
Why?
|
| Benzamides | 2 | 2024 | 1387 | 0.310 |
Why?
|
| Disease-Free Survival | 5 | 2022 | 6856 | 0.310 |
Why?
|
| Hospital Mortality | 8 | 2015 | 5369 | 0.300 |
Why?
|
| Glucocorticoids | 1 | 2017 | 2167 | 0.300 |
Why?
|
| Anemia | 1 | 2017 | 1517 | 0.300 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 496 | 0.300 |
Why?
|
| Prostate | 4 | 2023 | 1781 | 0.290 |
Why?
|
| Humans | 74 | 2024 | 768970 | 0.290 |
Why?
|
| Myeloma Proteins | 2 | 2018 | 71 | 0.290 |
Why?
|
| Salvage Therapy | 2 | 2024 | 1277 | 0.280 |
Why?
|
| Middle Aged | 38 | 2024 | 223737 | 0.280 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 1626 | 0.280 |
Why?
|
| Disease Management | 2 | 2020 | 2537 | 0.270 |
Why?
|
| Treatment Outcome | 25 | 2024 | 65480 | 0.270 |
Why?
|
| Cisplatin | 3 | 2022 | 1661 | 0.270 |
Why?
|
| Deoxycytidine | 2 | 2021 | 888 | 0.270 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 1907 | 0.260 |
Why?
|
| Robotics | 4 | 2013 | 826 | 0.250 |
Why?
|
| Inpatients | 3 | 2013 | 2569 | 0.250 |
Why?
|
| Hospitalization | 3 | 2014 | 10847 | 0.240 |
Why?
|
| Methotrexate | 2 | 2021 | 1723 | 0.230 |
Why?
|
| Doxorubicin | 2 | 2021 | 2234 | 0.230 |
Why?
|
| Postoperative Complications | 12 | 2016 | 15889 | 0.230 |
Why?
|
| Surgical Procedures, Operative | 1 | 2015 | 1941 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 6547 | 0.220 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2023 | 48 | 0.220 |
Why?
|
| Healthcare Disparities | 3 | 2015 | 3421 | 0.220 |
Why?
|
| Suicide | 1 | 2014 | 1606 | 0.210 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2024 | 168 | 0.210 |
Why?
|
| Surgical Wound Infection | 1 | 2012 | 1547 | 0.210 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 8559 | 0.190 |
Why?
|
| Depressive Disorder | 1 | 2014 | 3723 | 0.190 |
Why?
|
| Immunotherapy | 4 | 2020 | 4756 | 0.190 |
Why?
|
| Retrospective Studies | 21 | 2024 | 81903 | 0.180 |
Why?
|
| Disease Progression | 6 | 2022 | 13674 | 0.170 |
Why?
|
| Camptothecin | 1 | 2023 | 600 | 0.170 |
Why?
|
| Teratoma | 1 | 2023 | 405 | 0.170 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2022 | 257 | 0.170 |
Why?
|
| Insulin Resistance | 2 | 2024 | 3982 | 0.170 |
Why?
|
| Anxiety | 1 | 2014 | 4672 | 0.160 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 325 | 0.160 |
Why?
|
| Hormones | 1 | 2023 | 870 | 0.160 |
Why?
|
| Taxoids | 3 | 2022 | 668 | 0.160 |
Why?
|
| Proportional Hazards Models | 6 | 2021 | 12562 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 3 | 2024 | 3629 | 0.150 |
Why?
|
| Survival Rate | 3 | 2018 | 12873 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 1793 | 0.150 |
Why?
|
| Adult | 19 | 2024 | 223851 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 878 | 0.150 |
Why?
|
| United States | 18 | 2024 | 73186 | 0.150 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 906 | 0.150 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2024 | 1514 | 0.140 |
Why?
|
| Female | 27 | 2024 | 397515 | 0.140 |
Why?
|
| Time Factors | 9 | 2024 | 40261 | 0.140 |
Why?
|
| Risk Factors | 10 | 2024 | 74976 | 0.140 |
Why?
|
| Bone Marrow | 2 | 2018 | 2936 | 0.140 |
Why?
|
| Length of Stay | 7 | 2015 | 6526 | 0.140 |
Why?
|
| Muscle, Smooth | 1 | 2021 | 931 | 0.140 |
Why?
|
| Laparoscopy | 3 | 2014 | 2055 | 0.140 |
Why?
|
| Androstenes | 2 | 2016 | 186 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2024 | 1384 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 3554 | 0.130 |
Why?
|
| Prognosis | 9 | 2024 | 30046 | 0.130 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 2001 | 0.130 |
Why?
|
| Internationality | 1 | 2021 | 1008 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 1060 | 0.120 |
Why?
|
| Urinary Bladder | 1 | 2021 | 1162 | 0.120 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2013 | 1006 | 0.120 |
Why?
|
| Orchiectomy | 3 | 2023 | 468 | 0.120 |
Why?
|
| Androstenols | 1 | 2014 | 25 | 0.120 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 4363 | 0.110 |
Why?
|
| Multivariate Analysis | 7 | 2015 | 12095 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 1616 | 0.110 |
Why?
|
| Neoplasms | 4 | 2016 | 22389 | 0.110 |
Why?
|
| Lymph Node Excision | 2 | 2023 | 1273 | 0.110 |
Why?
|
| Decompression | 1 | 2012 | 36 | 0.100 |
Why?
|
| Plasma Cells | 1 | 2016 | 599 | 0.100 |
Why?
|
| Databases, Factual | 6 | 2024 | 8094 | 0.100 |
Why?
|
| Urogenital Neoplasms | 1 | 2013 | 132 | 0.100 |
Why?
|
| Intraoperative Complications | 3 | 2013 | 1176 | 0.100 |
Why?
|
| SEER Program | 2 | 2014 | 1473 | 0.100 |
Why?
|
| Rare Diseases | 1 | 2017 | 631 | 0.100 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2012 | 79 | 0.100 |
Why?
|
| Hospital Charges | 1 | 2013 | 351 | 0.100 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 472 | 0.100 |
Why?
|
| Urinary Catheterization | 1 | 2012 | 195 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2021 | 1346 | 0.090 |
Why?
|
| Remission Induction | 1 | 2017 | 2408 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2020 | 10115 | 0.090 |
Why?
|
| Bone Neoplasms | 2 | 2013 | 2565 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2024 | 24333 | 0.090 |
Why?
|
| Kidney Pelvis | 1 | 2012 | 195 | 0.090 |
Why?
|
| Urolithiasis | 1 | 2012 | 125 | 0.090 |
Why?
|
| Cohort Studies | 7 | 2023 | 41808 | 0.090 |
Why?
|
| Odds Ratio | 4 | 2016 | 9684 | 0.090 |
Why?
|
| North America | 1 | 2014 | 1290 | 0.090 |
Why?
|
| Ureteral Obstruction | 1 | 2012 | 297 | 0.090 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2014 | 497 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2016 | 1531 | 0.090 |
Why?
|
| Area Under Curve | 1 | 2014 | 1645 | 0.080 |
Why?
|
| Urologic Surgical Procedures | 1 | 2012 | 299 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 957 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 3671 | 0.080 |
Why?
|
| Peptide YY | 1 | 2010 | 135 | 0.080 |
Why?
|
| Hospital Administration | 1 | 2013 | 353 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 13698 | 0.080 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 39394 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 2916 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2024 | 9384 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 1120 | 0.080 |
Why?
|
| Logistic Models | 5 | 2014 | 13318 | 0.080 |
Why?
|
| Registries | 1 | 2024 | 8384 | 0.070 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 1014 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2013 | 1913 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2024 | 7885 | 0.070 |
Why?
|
| Puberty | 1 | 2010 | 501 | 0.070 |
Why?
|
| Biopsy | 1 | 2018 | 6805 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9264 | 0.070 |
Why?
|
| Blood Transfusion | 4 | 2015 | 1309 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 14794 | 0.070 |
Why?
|
| Patient Admission | 1 | 2013 | 1370 | 0.070 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 805 | 0.070 |
Why?
|
| ROC Curve | 1 | 2014 | 3629 | 0.060 |
Why?
|
| Androgens | 2 | 2023 | 1285 | 0.060 |
Why?
|
| Human Growth Hormone | 1 | 2010 | 651 | 0.060 |
Why?
|
| Pneumonia | 1 | 2016 | 2164 | 0.060 |
Why?
|
| Quality of Life | 2 | 2023 | 13510 | 0.060 |
Why?
|
| Cross Infection | 1 | 2013 | 1425 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2024 | 54962 | 0.060 |
Why?
|
| Hospitals | 2 | 2016 | 3904 | 0.050 |
Why?
|
| Castration | 1 | 2023 | 150 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 5375 | 0.050 |
Why?
|
| Age Factors | 3 | 2014 | 18435 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2015 | 1886 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 3438 | 0.050 |
Why?
|
| Carcinoma | 1 | 2013 | 2340 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7460 | 0.050 |
Why?
|
| Melanoma | 1 | 2019 | 5709 | 0.050 |
Why?
|
| Adolescent | 4 | 2018 | 89244 | 0.050 |
Why?
|
| Propensity Score | 3 | 2013 | 1968 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2015 | 3860 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 640 | 0.040 |
Why?
|
| Mental Health | 1 | 2014 | 3275 | 0.040 |
Why?
|
| Prednisone | 1 | 2024 | 1567 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 357 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2020 | 551 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 560 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2013 | 4339 | 0.040 |
Why?
|
| Incidence | 2 | 2013 | 21547 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 1019 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2024 | 1064 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 30266 | 0.040 |
Why?
|
| HIV Infections | 1 | 2024 | 17591 | 0.040 |
Why?
|
| Tubulin Modulators | 1 | 2016 | 106 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2020 | 498 | 0.030 |
Why?
|
| Minority Groups | 1 | 2023 | 1216 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2360 | 0.030 |
Why?
|
| Young Adult | 3 | 2019 | 60131 | 0.030 |
Why?
|
| Body Composition | 1 | 2024 | 2462 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 5707 | 0.030 |
Why?
|
| Mid-Atlantic Region | 1 | 2013 | 24 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 7957 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2013 | 6346 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 1625 | 0.030 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2013 | 86 | 0.030 |
Why?
|
| Risk | 2 | 2016 | 9621 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 2734 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2013 | 5956 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2019 | 2437 | 0.020 |
Why?
|
| Laparotomy | 1 | 2014 | 459 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2013 | 252 | 0.020 |
Why?
|
| Esophagectomy | 1 | 2015 | 482 | 0.020 |
Why?
|
| New England | 1 | 2013 | 1058 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 2015 | 825 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2015 | 693 | 0.020 |
Why?
|
| Colectomy | 1 | 2015 | 699 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2015 | 866 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 4978 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 13594 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 2862 | 0.020 |
Why?
|
| Liver | 1 | 2024 | 7578 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 4651 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2013 | 1830 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 2015 | 1159 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 2932 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2014 | 1313 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2015 | 1045 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 11116 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 1422 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2013 | 792 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 8664 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 8055 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2013 | 1960 | 0.010 |
Why?
|
| Cause of Death | 1 | 2014 | 3721 | 0.010 |
Why?
|
| Linear Models | 1 | 2013 | 5891 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 2784 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 26395 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7861 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2013 | 2518 | 0.010 |
Why?
|
| Medicaid | 1 | 2013 | 2843 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2010 | 2649 | 0.010 |
Why?
|
| Algorithms | 1 | 2020 | 14201 | 0.010 |
Why?
|
| Sex Factors | 1 | 2012 | 10633 | 0.010 |
Why?
|
| Sepsis | 1 | 2012 | 2610 | 0.010 |
Why?
|
| Comorbidity | 1 | 2013 | 10592 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2010 | 6435 | 0.010 |
Why?
|
| Medicare | 1 | 2013 | 6888 | 0.010 |
Why?
|
| Child | 1 | 2010 | 80960 | 0.000 |
Why?
|